Concepedia

First-in-human phase I study of the bromodomain and extraterminal motif inhibitor BAY 1238097: emerging pharmacokinetic/pharmacodynamic relationship and early termination due to unexpected toxicity

Sophie Postel‐Vinay, Karin H. Herbschleb, Christophe Massard, Victoria K. Woodcock, Jean‐Charles Soria, Annette O. Walter, Flavio Ewerton, Martine Poelman, Neil Benson, Matthias Ocker,

European Journal of Cancer · 2019 · 104 citations · 15 references

DOIFull text

Open access

Concepts

References

15

Selective inhibition of BET bromodomains

P. Filippakopoulos, Jun Qi, S. Picaud et al. · Nature · 2010 · 4.3K citations · Full text

, , +5

The landscape of somatic copy-number alteration across human cancers

Rameen Beroukhim, Craig H. Mermel, Dale Porter et al. · Nature · 2010 · 4.1K citations · Full text

, , +14

BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc

Jake Delmore, Ghayas C. Issa, Madeleine E. Lemieux et al. · Cell · 2011 · 2.8K citations · Full text

, , +10

Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer

Irfan A. Asangani, Vijaya L. Dommeti, Xiaoju Wang et al. · Nature · 2014 · 952 citations · Full text

, , +16

Discovery and Characterization of Super-Enhancer-Associated Dependencies in Diffuse Large B Cell Lymphoma

Bjoern Chapuy, Michael R. McKeown, Charles Y. Lin et al. · Cancer Cell · 2013 · 766 citations · Full text

, , +17